Nav: Home

Stem cell transplantation does not provide significant improvement for Crohn's disease

December 17, 2015

A clinical trial to test the effectiveness of a stem cell therapy among adults with difficult to treat Crohn's disease has found it is not significantly better than conventional treatment in producing sustained disease remission after one year.

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract causing pain and diarrhoea that can mean life-long ill health, impaired quality of life and reduced life expectancy. About one in 200 people in developed countries suffer from Crohn disease or ulcerative colitis. Immunosuppressive drugs are the standard treatment for Crohn's but some patients do not respond to it, or lose response to it over time.

Patient case reports had suggested that blood stem cell transplantation (HSCT) may help some patients so an international randomised clinical trial was set up by the Nottingham Digestive Diseases Centre (NDDC) to test this hypothesis. The results are published in the Journal of the American Medical Association.

The researchers randomly assigned 45 patients with Crohn's disease who were not responsive to treatment or suitable for surgery to autologous (the use of one's own cells) blood stem cell treatment or a control treatment in groups of 23 and 22. Patients were aged between 18 and 50 years and all were given standard Crohn's treatment as needed. The trial involved 11 European transplant units from July 2007 to September 2011 with follow-up until March 2013.

Leading the trial, Professor Chris Hawkey of the Nottingham Digestive Diseases Centre, said: "We found there was no statistically significant difference between the groups in the proportion of patients who met our highly stringent definition of sustained disease remission after treatment -- only two in the stem cell transplant group (8.7 percent) and one in the control group (4.5 percent). However, there was a significant difference among patients able to discontinue active treatment in the last three months of participation in the trial -- 61 percent in the stem cell group and 23 per cent in the control, and objective signs of disease disappeared in about a quarter of patients.

"There were 76 serious adverse events in patients undergoing stem cell therapy and 38 in the control group. Because very few patients achieved sustained disease remission, we conclude that HSCT is unlikely to alter the natural history of Crohn disease, and our findings argue against extension of HSCT to a wider group of patients outside of future additional trials."

Professor Dominique Farge Bancel, Saint Louis Hospital in Paris and Chair of the European Blood and Marrow Transplantation Society, added: "Although autologous HSCT therapy showed more toxicity in early stages of the follow-up in Crohn's patients, long term results after HSCT treatment may shed new lights on the expected benefit, as observed in Scleroderma, another autoimmune disease where the proof of a HSCT superiority over conventional therapy was obtained only after long term follow-up at the price of higher early toxicity."

The research concludes that further study of HSCT in patients with Crohn's disease which does not respond to standard treatment is needed. It recommends that future trials should examine the benefit of maintenance immunosuppressive therapy after HSCT and also an investigation of whether patients may regain responsiveness to treatments which were previously ineffective for them. As toxicity is the most significant barrier to HSCT in patients with Crohn's, more work is also needed to identify factors that predict either the risk of adverse effects or response to treatment to enhance the use of stem cell therapy in clinical practice.
-end-
The trial was a collaborative project conducted by leading entities in the fields of Bone Marrow Transplantation and Gastroenterology: the European Society for Blood and Marrow Transplantation (EBMT) and the European Crohn's and Colitis Organisation (ECCO) and funded by the Broad Medical Foundation and the Nottingham Digestive Diseases Centre.

University of Nottingham

Related Clinical Trial Articles:

Landmark clinical trial to help juvenile idiopathic arthritis sufferers
A clinical trial funded by Arthritis Research UK and the National Institute for Health Research led by professors from the universities of Liverpool and Bristol has discovered a drug combination that could help thousands of children with arthritis.
Clinical trial for new innovative osteoarthritis drug
The University of Liverpool, in partnership with AKL Research and Development Ltd, is to lead on a clinical trial to test a potential new drug treatment for osteoarthritis.
New malaria vaccine effective in clinical trial
University of Tuebingen researchers in collaboration with the biotech company Sanaria Inc. have demonstrated in a clinical trial that a new vaccine for malaria called Sanaria® PfSPZ-CVac has been up to 100 percent effective when assessed at 10 weeks after last dose of vaccine.
Clinical trial of infection detecting bandages begins
A clinical trial of a smart bandage which changes color when it detects infections is beginning using samples from burns patients from four UK hospitals.
First human clinical trial for nicotinamide riboside
In the first controlled clinical trial of nicotinamide riboside (NR), a newly discovered form of vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage.
Tapping into behavioral economics to boost clinical trial participation
Behavioral economics may offer a powerful tool for improving patient enrollment in clinical trials, argue Eric VanEpps, Kevin Volpp, and Scott Halpern in this Focus.
Clinical trial examines treatment of complicated grief
A new study reports on the results of a randomized clinical trial that looked at whether the antidepressant citalopram would enhance complicated grief treatment psychotherapy, and if citalopram would be efficacious without it in an article published online by JAMA Psychiatry.
Crossref Publishers deliver win for clinical trial openness
At the click of a button, health professionals and researchers will now be able to view all of the clinical trials referenced in the paper they are reading, and any related publications such as the protocol, statistical analysis plan, and results articles.
New database for sharing MS clinical trial data
The Multiple Sclerosis Outcome Assessments Consortium (MSOAC), a global effort of the National MS Society and Critical Path Institute (C-Path), is launching a database, accessible to qualified researchers, containing trial data from nearly 2,500 patients from the placebo arms of nine MS clinical trials.
Clinical trial for experimental Ebola drug publishes results
Results of the Wellcome Trust funded trial of the experimental anti-Ebola drug TKM-130803 published in PLOS Medicine.

Related Clinical Trial Reading:

Fundamentals of Clinical Trials
by Lawrence M. Friedman (Author), Curt D. Furberg (Author), David L. DeMets (Author), David M. Reboussin (Author), Christopher B. Granger (Author)

This is the fifth edition of a very successful textbook on clinical trials methodology, written by recognized leaders who have long and extensive experience in all areas of clinical trials. The three authors of the first four editions have been joined by two others who add great expertise. A chapter on regulatory issues has been included and the chapter on data monitoring has been split into two and expanded. Many contemporary clinical trial examples have been added. There is much new material on adverse events, adherence, issues in analysis, electronic data, data sharing and... View Details


Clinical Trials: A Methodologic Perspective Second Edition(Wiley Series in Probability and Statistics)
by Steven Piantadosi (Author)

Learn rigorous statistical methods to ensure valid clinical trials

This Second Edition of the critically hailed Clinical Trials builds on the text's reputation as a straightforward and authoritative presentation of statistical methods for clinical trials. Readers are introduced to the fundamentals of design for various types of clinical trials and then skillfully guided through the complete process of planning the experiment, assembling a study cohort, assessing data, and reporting results. Throughout the process, the author alerts readers to problems that may arise during the... View Details


Clinical Trials, Second Edition: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines
by Tom Brody PhD (Author)

Clinical Trials, Second Edition, offers those engaged in clinical trial design a valuable and practical guide. This book takes an integrated approach to incorporate biomedical science, laboratory data of human study, endpoint specification, legal and regulatory aspects and much more with the fundamentals of clinical trial design. It provides an overview of the design options along with the specific details of trial design and offers guidance on how to make appropriate choices. Full of numerous examples and now containing actual decisions from FDA reviewers to better inform trial... View Details


A Clinical Trials Manual From The Duke Clinical Research Institute: Lessons from a Horse Named Jim
by Margaret Liu (Author), Kate Davis (Author)

"The publication of the second edition of this manual comes at an important juncture in the history of clinical research. As advances in information technology make it possible to link individuals and groups in diverse locations in jointly seeking the answers to pressing global health problems, it is critically important to remain vigilant about moral and ethical safeguards for every patient enrolled in a trial. Those who study this manual will be well aware of how to ensure patient safety along with fiscal responsibility, trial efficiency, and research integrity."
Robert... View Details


A Concise Guide to Clinical Trials
by J. Rick Turner PhD (Author)

Biopharmaceutical drugs improve the health and well-being of people across the globe on a scale that is unrivaled by any other medical intervention. Before these drugs can be prescribed for patients by their doctors, they have to be approved for marketing by a regulatory agency. To gain marketing approval, drugs must go through an extremely rigorous process that investigates their safety and efficacy, the process of New Drug Development. The last stage of this long, complex, and expensive process involves conducting clinical trials, the topic of this book. Successfully conducting clinical... View Details


Clinical Trials in Oncology, Third Edition (Chapman & Hall/CRC Interdisciplinary Statistics)
by Stephanie Green (Author), Jacqueline Benedetti (Author), Angela Smith (Author), John Crowley (Author)

The third edition of the bestselling Clinical Trials in Oncology provides a concise, nontechnical, and thoroughly up-to-date review of methods and issues related to cancer clinical trials. The authors emphasize the importance of proper study design, analysis, and data management and identify the pitfalls inherent in these processes. In addition, the book has been restructured to have separate chapters and expanded discussions on general clinical trials issues, and issues specific to Phases I, II, and III. New sections cover innovations in Phase I designs, randomized Phase... View Details


Clinical Trials: A Practical Approach
by Stuart J. Pocock (Author)

This comprehensive, unified text on the principles and practice of clinical trials presents a detailed account of how to conduct the trials. It describes the design, analysis, and interpretation of clinical trials in a non-technical manner and provides a general perspective on their historical development, current status, and future strategy. Features examples derived from the author's personal experience. View Details


Surviving "Terminal" Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About
by Ben A. Williams Ph.D. (Author)

An account of dealing with glioblastoma brain cancer, along with the information needed to survive it View Details


Clinical Trials: What Patients and Healthy Volunteers Need to Know
by Lorna Speid Ph.D (Author)

Every year, hundreds of thousands of healthy volunteers and patients worldwide undertake the journey through the maze that can be clinical trials. Research participants take part in clinical trials for a variety of reasons. The healthy volunteers may be seeking extra money to pay off college tuition, or they may know someone who is suffering and would potentially benefit from the results of the trial. The patient who is terminally ill might participate in a clinical trial simply as a last hope for a cure. Whatever the goals, though, most participants will experience the same sense of... View Details


Clinical Trials: A Methodologic Perspective Second Edition(Wiley Series in Probability and Statistics) 2nd edition by Piantadosi, Steven (2005) Hardcover
by aa (Author)

View Details

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

The Big Five
What are the five biggest global challenges we face right now — and what can we do about them? This hour, TED speakers explore some radical solutions to these enduring problems. Guests include geoengineer Tim Kruger, president of the International Rescue Committee David Miliband, political scientist Ian Bremmer, global data analyst Sarah Menker, and historian Rutger Bregman.
Now Playing: Science for the People

#456 Inside a Conservation NGO
This week we take a close look at conservation NGOS: what they do, how they work, and - most importantly - why we need them. We'll be speaking with Shyla Raghav, the Climate Change Lead at Conservation International, about using strategy and policy to tackle climate change. Then we'll speak with Rebecca Shaw, Lead Scientist at the World Wildlife Fund, about how and why you should get involved with conservation initiatives.